ASCO 2015: Latest developments in multiple myeloma

Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma

Non-randomised clinical trial aims to describe the safety and efficacy of commercially available, targeted anticancer drugs

Developments in clinical trials and health information technology that will improve targeted therapies for patients

Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin lymphoma, genomic marker mismatch repair and myelofibrosis

New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

Pembrolizumab for head and neck cancer

Pembrolizumab shows promising activity against head and neck cancer

Prostate cancer and pharmacokinetics: Expert discussion

WIN 2015 hosts 'world class leaders' in personalised therapy